Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · IEX Real-Time Price · USD
1.520
-0.080 (-5.00%)
At close: Apr 26, 2024, 1:37 PM
1.490
-0.030 (-1.97%)
After-hours: Apr 26, 2024, 4:49 PM EDT
Cyclacel Pharmaceuticals Stock Forecast
CYCC's stock price has decreased by -83.69% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CYCC stock have an average target of 70.5, with a low estimate of 21 and a high estimate of 120. The average target predicts an increase of 4,538.16% from the current stock price of 1.52.
Analyst Consensus: Buy
* Price targets were last updated on Dec 19, 2023.
Analyst Ratings
The average analyst rating for CYCC stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 19, 2023 |
| Roth MKM | Roth MKM | Strong Buy Maintains $16 → $21 | Strong Buy | Maintains | $16 → $21 | +1,281.58% | Dec 19, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $120 | Buy | Maintains | $120 | +7,794.74% | May 25, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $150 → $120 | Buy | Maintains | $150 → $120 | +7,794.74% | Mar 7, 2023 |
| Oppenheimer | Oppenheimer | Buy Initiates $255 | Buy | Initiates | $255 | +16,676.32% | Jul 18, 2022 |
Financial Forecast
Revenue This Year
n/a
from 420.00K
Revenue Next Year
n/a
EPS This Year
-13.65
from -26.75
EPS Next Year
-24.86
from -13.65
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 245.5M | 153.8M | 214.4M |
| Avg | n/a | n/a | 155.6M | 149.4M | 208.2M |
| Low | n/a | n/a | 69.9M | 143.6M | 200.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | -1.2% | 43.5% |
| Avg | - | - | - | -4.0% | 39.4% |
| Low | - | - | - | -7.7% | 33.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -14.05 | -25.59 | 1.85 | 3.84 | 5.51 |
| Avg | -13.65 | -24.86 | 1.70 | 3.73 | 5.36 |
| Low | -13.11 | -23.88 | 1.54 | 3.59 | 5.15 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 126.3% | 47.7% |
| Avg | - | - | - | 119.8% | 43.4% |
| Low | - | - | - | 111.2% | 37.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.